BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17487387)

  • 1. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
    Takao M; Okamoto A; Nikaido T; Urashima M; Takakura S; Saito M; Saito M; Okamoto S; Takikawa O; Sasaki H; Yasuda M; Ochiai K; Tanaka T
    Oncol Rep; 2007 Jun; 17(6):1333-9. PubMed ID: 17487387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.
    Ino K; Yoshida N; Kajiyama H; Shibata K; Yamamoto E; Kidokoro K; Takahashi N; Terauchi M; Nawa A; Nomura S; Nagasaka T; Takikawa O; Kikkawa F
    Br J Cancer; 2006 Dec; 95(11):1555-61. PubMed ID: 17117179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival.
    Ino K; Yamamoto E; Shibata K; Kajiyama H; Yoshida N; Terauchi M; Nawa A; Nagasaka T; Takikawa O; Kikkawa F
    Clin Cancer Res; 2008 Apr; 14(8):2310-7. PubMed ID: 18413819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
    Witkiewicz A; Williams TK; Cozzitorto J; Durkan B; Showalter SL; Yeo CJ; Brody JR
    J Am Coll Surg; 2008 May; 206(5):849-54; discussion 854-6. PubMed ID: 18471709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
    Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of indoleamine 2,3-dioxygenase expression in patients with breast cancer].
    Sakurai K; Amano S; Enomoto K; Kashio M; Saito Y; Sakamoto A; Matsuo S; Suzuki M; Kitajima A; Hirano T; Negishi N
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1546-9. PubMed ID: 16315864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
    Brandacher G; Perathoner A; Ladurner R; Schneeberger S; Obrist P; Winkler C; Werner ER; Werner-Felmayer G; Weiss HG; Göbel G; Margreiter R; Königsrainer A; Fuchs D; Amberger A
    Clin Cancer Res; 2006 Feb; 12(4):1144-51. PubMed ID: 16489067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary.
    Terauchi F; Okamoto A; Nagashima T; Kobayashi Y; Moritake T; Yamamoto Y; Takakura S; Iwaki S; Ogura H
    Oncol Rep; 2005 Aug; 14(2):363-8. PubMed ID: 16012716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
    Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
    Riesenberg R; Weiler C; Spring O; Eder M; Buchner A; Popp T; Castro M; Kammerer R; Takikawa O; Hatz RA; Stief CG; Hofstetter A; Zimmermann W
    Clin Cancer Res; 2007 Dec; 13(23):6993-7002. PubMed ID: 18056175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 May; 30(5):614-24. PubMed ID: 16699316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining.
    Kritpracha K; Hanprasertpong J; Chandeying V; Dechsukhum C; Geater A
    J Obstet Gynaecol Res; 2005 Jun; 31(3):268-76. PubMed ID: 15916666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
    Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
    Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
    Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
    APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of glutathione S-transferase-pi in operative specimens as marker of chemoresistance in patients with ovarian cancer].
    Huang J; Gu M; Chen C
    Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):458-61. PubMed ID: 9639737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase 2 expression in serous tumors of the ovary.
    Singhal PK; Spiegel G; Driscoll D; Odunsi K; Lele S; Rodabaugh KJ
    Int J Gynecol Pathol; 2005 Jan; 24(1):62-6. PubMed ID: 15626918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical analysis of 91 cases of hereditary breast and ovarian cancer].
    Li N; Wu LY; Zhang R; Zhang X; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2005 Apr; 27(4):245-7. PubMed ID: 15949430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H
    Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.